DK1819227T3 - Farmaceutisk formulering af decitabin - Google Patents
Farmaceutisk formulering af decitabinInfo
- Publication number
- DK1819227T3 DK1819227T3 DK05853560.0T DK05853560T DK1819227T3 DK 1819227 T3 DK1819227 T3 DK 1819227T3 DK 05853560 T DK05853560 T DK 05853560T DK 1819227 T3 DK1819227 T3 DK 1819227T3
- Authority
- DK
- Denmark
- Prior art keywords
- decitabine
- methods
- pharmaceutical formulation
- pharmaceutical formulations
- formulations
- Prior art date
Links
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 title abstract 5
- 229960003603 decitabine Drugs 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 cyclodextrin compound Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/009,540 US20060128653A1 (en) | 2004-12-10 | 2004-12-10 | Pharmaceutical formulation of decitabine |
| PCT/US2005/044676 WO2006071491A1 (en) | 2004-12-10 | 2005-12-08 | Pharmaceutical formulation of decitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1819227T3 true DK1819227T3 (da) | 2011-05-30 |
Family
ID=36584811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05853560.0T DK1819227T3 (da) | 2004-12-10 | 2005-12-08 | Farmaceutisk formulering af decitabin |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060128653A1 (da) |
| EP (1) | EP1819227B1 (da) |
| JP (1) | JP5227029B2 (da) |
| AT (1) | ATE497770T1 (da) |
| AU (1) | AU2005322369B2 (da) |
| CA (1) | CA2589052A1 (da) |
| CY (1) | CY1111433T1 (da) |
| DE (1) | DE602005026313D1 (da) |
| DK (1) | DK1819227T3 (da) |
| ES (1) | ES2360125T3 (da) |
| PL (1) | PL1819227T3 (da) |
| PT (1) | PT1819227E (da) |
| SI (1) | SI1819227T1 (da) |
| WO (1) | WO2006071491A1 (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US20070105792A1 (en) * | 2005-11-04 | 2007-05-10 | Dimartino Jorge F | Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases |
| US20090075920A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched decitabine |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| CA2753641C (en) * | 2009-02-25 | 2014-09-16 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US8383663B2 (en) * | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| US10052345B2 (en) | 2010-10-19 | 2018-08-21 | University Of Miami | Assays, methods and kits for predicting renal disease and personalized treatment strategies |
| JP2014503597A (ja) * | 2011-01-31 | 2014-02-13 | セルジーン コーポレイション | シチジンアナログの医薬組成物及びその使用方法 |
| EP2726106B1 (en) * | 2011-07-01 | 2015-07-29 | Fondazione Istituto Insubrico di Ricerca per la Vita | A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof |
| PH12018501678B1 (en) | 2011-08-30 | 2022-08-10 | Astex Pharmaceuticals Inc | Decitabine derivative formulations |
| EP4083075A1 (en) | 2012-02-15 | 2022-11-02 | CyDex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| HK1211311A1 (en) | 2012-02-28 | 2016-05-20 | 锡德克斯药物公司 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
| US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
| EP2836221B1 (en) * | 2012-04-13 | 2023-07-05 | L&F Research LLC | Method of using cyclodextrin |
| US9493500B2 (en) | 2012-07-19 | 2016-11-15 | Richard Daifuku | Fluorinated pyrimidine analogs and methods of use thereof |
| HK1213585A1 (zh) | 2012-10-22 | 2016-07-08 | Cydex Pharmaceuticals, Inc. | 烷基化环糊精组合物及其制备和使用方法 |
| JP2016513699A (ja) * | 2013-03-15 | 2016-05-16 | エピザイム，インコーポレイティド | 癌の治療のための注射製剤 |
| CN105229020B (zh) * | 2013-03-15 | 2018-09-25 | 表观遗传学药业有限责任公司 | 氟化嘧啶类似物及其使用方法 |
| IL247301B (en) * | 2014-02-20 | 2022-07-01 | Vaxart Inc | Formulations for small intestinal delivery |
| MY182793A (en) * | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| PT3183295T (pt) | 2014-08-22 | 2023-11-03 | Cydex Pharmaceuticals Inc | Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas |
| CA2960287A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Injectable formulations for treating cancer |
| CN104887632B (zh) * | 2015-05-25 | 2017-10-24 | 连云港杰瑞药业有限公司 | 一种地西他滨冻干制剂的制备方法及其产品 |
| EP3307239B1 (en) | 2015-06-12 | 2020-09-16 | Vaxart, Inc. | Formulations for small intestinal delivery of rsv and norovirus antigens |
| EP3316685A4 (en) * | 2015-07-02 | 2019-03-13 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized Pharmaceutical Compositions |
| CA3007357C (en) | 2015-12-03 | 2023-12-05 | Epidestiny, Inc. | Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof |
| EP3661522A2 (en) | 2017-08-03 | 2020-06-10 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
| EP4274577A4 (en) * | 2021-01-06 | 2025-03-12 | Inaya Therapeutics, Inc. | FORMULATION OF INHALABLE IMATINIB |
| IL316061A (en) * | 2022-04-22 | 2024-11-01 | Universit?T Heidelberg | The composition including cytidine analogs and their uses and methods |
| US20260041704A1 (en) * | 2022-08-03 | 2026-02-12 | Beren Therapeutics P.B.C. | Compositions and methods for treating sickle cell disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2012888C3 (de) * | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
| US4684630A (en) * | 1983-08-24 | 1987-08-04 | Repta Arnold J | Method of parenterally delivering drugs and related compositions |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| US5736531A (en) * | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5856090A (en) * | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
| US5856094A (en) * | 1995-05-12 | 1999-01-05 | The Johns Hopkins University School Of Medicine | Method of detection of neoplastic cells |
| US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
| CA2241255A1 (en) * | 1995-12-22 | 1997-07-03 | East Carolina University | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
| US6423692B2 (en) * | 1997-04-24 | 2002-07-23 | Dana-Farber Cancer Institute, Inc. | Method of enhancing the effectiveness of DCK phosphorylated molecules |
| US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| AU5128999A (en) * | 1998-07-24 | 2000-02-14 | Yeda Research And Development Co. Ltd. | Prevention of metastasis with 5-aza-2'-deoxycytidine |
| US20020136709A1 (en) * | 2000-12-12 | 2002-09-26 | Nucleus Remodeling, Inc. | In vitro-derived adult pluripotent stem cells and uses therefor |
| US20030165864A1 (en) * | 2001-01-16 | 2003-09-04 | Lasek Amy W. | Genes regulated by DNA methylation in tumor cells |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US20030013099A1 (en) * | 2001-03-19 | 2003-01-16 | Lasek Amy K. W. | Genes regulated by DNA methylation in colon tumors |
| CN1520297A (zh) * | 2001-04-26 | 2004-08-11 | ���ߵ���Ƶϵͳ��˾ | 包含复合药物(codrugs)的缓释药物传递系统 |
| US20030045497A1 (en) * | 2001-07-27 | 2003-03-06 | Geneinvent Bbl Ab | Methylation resistant vectors |
| IN2014DN10834A (da) * | 2001-09-17 | 2015-09-04 | Psivida Inc | |
| US20030147813A1 (en) * | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
| US6927036B2 (en) * | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| WO2005014010A1 (en) * | 2003-07-24 | 2005-02-17 | Eli Lilly And Company | Pharmaceutical composition comprising gemcitabine and cyclodextrines |
| US20060063735A1 (en) * | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
-
2004
- 2004-12-10 US US11/009,540 patent/US20060128653A1/en not_active Abandoned
-
2005
- 2005-12-08 DK DK05853560.0T patent/DK1819227T3/da active
- 2005-12-08 WO PCT/US2005/044676 patent/WO2006071491A1/en not_active Ceased
- 2005-12-08 AT AT05853560T patent/ATE497770T1/de active
- 2005-12-08 ES ES05853560T patent/ES2360125T3/es not_active Expired - Lifetime
- 2005-12-08 DE DE602005026313T patent/DE602005026313D1/de not_active Expired - Lifetime
- 2005-12-08 CA CA002589052A patent/CA2589052A1/en not_active Abandoned
- 2005-12-08 PT PT05853560T patent/PT1819227E/pt unknown
- 2005-12-08 PL PL05853560T patent/PL1819227T3/pl unknown
- 2005-12-08 EP EP05853560A patent/EP1819227B1/en not_active Expired - Lifetime
- 2005-12-08 AU AU2005322369A patent/AU2005322369B2/en not_active Expired
- 2005-12-08 JP JP2007545673A patent/JP5227029B2/ja not_active Expired - Lifetime
- 2005-12-08 SI SI200531272T patent/SI1819227T1/sl unknown
-
2011
- 2011-04-28 CY CY20111100417T patent/CY1111433T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1819227B1 (en) | 2011-02-09 |
| SI1819227T1 (sl) | 2011-06-30 |
| CY1111433T1 (el) | 2015-08-05 |
| WO2006071491A1 (en) | 2006-07-06 |
| AU2005322369B2 (en) | 2010-10-28 |
| EP1819227A1 (en) | 2007-08-22 |
| EP1819227A4 (en) | 2008-07-23 |
| US20060128653A1 (en) | 2006-06-15 |
| AU2005322369A1 (en) | 2006-07-06 |
| JP2008523096A (ja) | 2008-07-03 |
| PL1819227T3 (pl) | 2011-07-29 |
| CA2589052A1 (en) | 2006-07-06 |
| ATE497770T1 (de) | 2011-02-15 |
| PT1819227E (pt) | 2011-04-29 |
| HK1102991A1 (en) | 2007-12-14 |
| DE602005026313D1 (de) | 2011-03-24 |
| ES2360125T3 (es) | 2011-06-01 |
| JP5227029B2 (ja) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111433T1 (el) | Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης | |
| WO2006063111A3 (en) | Pharmaceutical formulations cytidine analogs and derivatives | |
| DK2201840T3 (da) | Hæmmere af Brutons tyrosinkinase | |
| CY1119865T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον | |
| ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| BRPI0418251B8 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| MX2007010996A (es) | Nuevas composiciones de liposomas. | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| WO2006029081A3 (en) | Nucleoside-lipid conjugates, their method of preparation and uses thereof | |
| BRPI0410940A (pt) | benzo[b]tiofenos substituìdos com cicloalquilsulfanila como agentes terapêuticos | |
| NI200300045A (es) | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. | |
| UA94036C2 (ru) | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации | |
| BRPI0513287A (pt) | derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica | |
| NO20054723L (no) | Behandling av proliferative sykdommer med epofilonderivater og straling | |
| ATE346080T1 (de) | Steroid-verbindungen mit anti-tumoraler wirkung |